...
首页> 外文期刊>Journal of Neuro-Oncology >Expression and Functional Activity of the ABC-transporter Proteins P-glycoprotein and Multidrug-resistance Protein 1 in Human Brain Tumor Cells and Astrocytes
【24h】

Expression and Functional Activity of the ABC-transporter Proteins P-glycoprotein and Multidrug-resistance Protein 1 in Human Brain Tumor Cells and Astrocytes

机译:ABC转运蛋白P-糖蛋白和多药耐药蛋白1在人脑肿瘤细胞和星形胶质细胞中的表达和功能活性

获取原文
获取原文并翻译 | 示例
           

摘要

The poor prognosis of glioma patients is partly based on the minor success obtained from chemotherapeutic treatments. Resistance mechanisms at the tumor cell level may be, in addition to the blood–brain barrier, involved in the intrinsic chemo-insensitivity of brain tumors. We investigated the expression of the drug-transporter proteins P-glycoprotein (P-gp) and multidrug-resistance protein 1 (MRP1) in cell lines (N=24) and primary cell cultures (N=36) from neuroectodermal tumors, as well as in brain tumor extracts (N=18) and normal human astrocytes (N=1). We found that a considerable expression of P-gp was relatively rare in glioma cells, in contrast to MRP1, which was constitutively overexpressed in cells derived from astrocytomas as well as glioblastomas. Also, normal astrocytes cultured in vitro expressed high amounts of MRP1 but no detectable P-gp. Meningioma cells frequently co-expressed P-gp and MRP1, while, most of the neuroblastoma cell lines express higher P-gp but lower MRP1 levels as compared to the other tumor types. Both, a drug-exporting and a chemoprotective function of P-gp as well as MRP1 could be demonstrated in selected tumor cells by a significant upregulation of cellular 3H-daunomycin accumulation and daunomycin cytotoxicity via administration of transporter antagonists. Summing up, our data suggest that P-gp contributes to cellular resistance merely in a small subgroup of gliomas, but frequently in neuroblastomas and meningiomas. In contrast, MRP1 is demonstrated to play a constitutive role in the intrinsic chemoresistance of gliomas and their normal cell counterpart.
机译:神经胶质瘤患者的预后不良部分是基于从化学治疗中获得的较小成功。除血脑屏障外,肿瘤细胞水平的耐药机制还可能与脑肿瘤固有的化学不敏感性有关。我们研究了神经外胚层肿瘤中细胞系(N = 24)和原代细胞培养物(N = 36)中药物转运蛋白P-糖蛋白(P-gp)和多药耐药蛋白1(MRP1)的表达就像脑肿瘤提取物(N = 18)和正常人星形胶质细胞(N = 1)一样。我们发现,胶质瘤细胞中P-gp的大量表达相对较少,而MRP1与星形胶质细胞瘤和胶质母细胞瘤来源的细胞组成性地过表达。此外,体外培养的正常星形胶质细胞表达大量的MRP1,但未检测到P-gp。脑膜瘤细胞经常共表达P-gp和MRP1,而与其他类型的肿瘤相比,大多数成神经细胞瘤细胞系表达较高的P-gp但较低的MRP1水平。 P-gp以及MRP1的药物输出和化学保护功能都可以通过施用转运蛋白拮抗剂显着上调细胞3 H-道柔霉素的积累和道霉素的细胞毒性来证明。综上所述,我们的数据表明,P-gp仅在神经胶质瘤的一小部分中导致细胞抵抗,而在神经母细胞瘤和脑膜瘤中却很常见。相比之下,MRP1被证明在神经胶质瘤及其正常细胞对应物的内在化学耐药性中起组成性作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号